Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/ijms22115672
Keywords
COVID-19; NF-kappa B signaling; H1 receptor antagonists; treatment; drugs
Funding
- Sanming Project ofMedicine in Shenzhen [SZSM201911003]
- Research Start-up Fund of the Seventh Affiliated Hospital Sun Yat-sen University [ZSQYRSFPD0028]
Ask authors/readers for more resources
COVID-19 has become a global pandemic, necessitating urgent identification of therapies to limit SARS-CoV-2 infection and improve outcomes for COVID-19 patients. H1 receptor antagonists, commonly used for allergic diseases, show promise as anti-SARS-CoV-2 agents and may benefit clinical manifestations by reducing lung inflammation.
COVID-19 has rapidly become a pandemic worldwide, causing extensive and long-term health issues. There is an urgent need to identify therapies that limit SARS-CoV-2 infection and improve the outcome of COVID-19 patients. Unbalanced lung inflammation is a common feature in severe COVID-19 patients; therefore, reducing lung inflammation can undoubtedly benefit the clinical manifestations. Histamine H1 receptor (H1 receptor) antagonists are widely prescribed medications to treat allergic diseases, while recently it has emerged that they show significant promise as anti-SARS-CoV-2 agents. Here, we briefly summarize the novel use of H1 receptor antagonists in combating SARS-CoV-2 infection. We also describe the potential antiviral mechanisms of H1 receptor antagonists on SARS-CoV-2. Finally, the opportunities and challenges of the use of H1 receptor antagonists in managing COVID-19 are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available